A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Solid Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.9
2 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 248 (final count)
- Started
- Jul 22, 2020
- Main results expected
- Mar 30, 2026
- Fully finished
- Mar 30, 2026
- Results posted
- Oct 22, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Grade 3 or Higher TEAEs
Measured over: Up to approximately 68 months
Number of Participants With Dose-Limiting Toxicities (DLTs) During the Dose Escalation Phase
Measured over: During Cycle 1 (cycle length= 21 days)
Number of Participants Reporting One or More Treatment-emergent Serious Adverse Event (TESAEs)
Measured over: Up to approximately 68 months
Number of Participants With One or More TEAEs Leading to Dazostinag Dose Modifications and Treatment Discontinuations
Measured over: Up to approximately 68 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04420884 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC